500 kidney patients monitored to see how new antibody drugs perform over time

NCT ID NCT06242327

Recruiting now Disease control Sponsor: Mario Negri Institute for Pharmacological Research Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 26 times

Summary

This study follows 500 adults with primary membranous nephropathy, a kidney disease that causes protein leakage and swelling. Researchers will track how well patients respond to treatments like rituximab or other monoclonal antibodies in real-world settings. The goal is to understand long-term remission rates and disease progression. No new treatments are being tested; instead, the study observes outcomes from standard care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MEMBRANOUS NEPHROPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Email: •••••@•••••

Locations

ASST HPG23 - Unità di Nefrologia
ACTIVE_NOT_RECRUITING

Bergamo, BG, 24127, Italy
Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò"
RECRUITING

Ranica, BG, 24020, Italy

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

MEMBRANOUS NEPHROPATHY